ALTIUM CAPITAL MANAGEMENT LP
Q3 2022 Form 13-F
NEW YORK, NEW YORK
CIK 0001746382
· Institutional investment manager
$272.8M Reported Value Total
Reported value
$272.8M
Quarter over quarter
+8.8%
Holdings
130
Top-10 concentration
26.6%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Mark Gottlieb
Chief Operating Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2022 13F record
Q3 2022 13F filing summary
| Period of report | September 30, 2022 |
|---|---|
| Filed | November 14, 2022 |
| Form | 13F-HR |
| Reported value | $272.8M |
| Positions | 130 |
| Change in reported value | +9.1% |
| New positions | 38 |
| Exited positions | 28 |
| Position turnover | 41.8% |
| Top-10 concentration | 26.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 4, 2026
|
20 | $68.8M |
|
Q2 2026 13F
Filed Aug 12, 2026
|
19 | $47.5M |
|
Q1 2026 13F
Filed May 1, 2026
|
19 | $42.0M |
|
Q4 2025 13F
Filed Feb 6, 2026
|
18 | $25.3M |
|
Q3 2025 13F
Filed Nov 4, 2025
|
1 | $628.3K |
|
Q2 2025 13F
Filed Aug 7, 2025
|
0 | $0 |
|
Q1 2025 13F
Filed May 9, 2025
|
22 | $41.5M |
|
Q4 2024 13F
Filed Feb 13, 2025
|
61 | $352.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
75 | $339.7M |
|
Q2 2024 13F
Filed Aug 15, 2024
|
64 | $245.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
67 | $252.7M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
62 | $147.3M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
65 | $191.7M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
63 | $132.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
88 | $180.1M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
91 | $196.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
130 | $272.8M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
120 | $249.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
117 | $298.8M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
131 | $362.7M |
4 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | BLU BELLUS HEALTH INC NEW | $12.0M | 4.38% |
| 2 | KDNY CHINOOK THERAPEUTICS INC | $10.3M | 3.78% |
| 3 | CCXI CHEMOCENTRYX INC | $8.3M | 3.03% |
| 4 | PEPL PEPPERLIME HEALTH ACQUSTN CO | $7.3M | 2.69% |
| 5 | ADMA ADMA BIOLOGICS INC | $7.0M | 2.57% |
| 6 | CBAY CYMABAY THERAPEUTICS INC | $6.1M | 2.25% |
| 7 | INSM INSMED INC | $5.8M | 2.12% |
| 8 | GH C GUARDANT HEALTH INC | $5.4M | 1.97% |
| 9 | MBTC NOCTURNE ACQUISITION CORP | $5.2M | 1.89% |
| 10 | GKOS GLAUKOS CORP | $5.2M | 1.89% |
| 11 | AKRO AKERO THERAPEUTICS INC | $4.8M | 1.75% |
| 12 | ITCI INTRA-CELLULAR THERAPIES INC | $4.7M | 1.71% |
| 13 | BONE XTANT MED HLDGS INC | $4.5M | 1.65% |
| 14 | PLRX PLIANT THERAPEUTICS INC | $4.5M | 1.65% |
| 15 | ESPR ESPERION THERAPEUTICS INC NE | $4.4M | 1.62% |
| 16 | BCAB BIOATLA INC | $4.3M | 1.56% |
| 17 | ILMN ILLUMINA INC | $4.2M | 1.54% |
| 18 | RYTM RHYTHM PHARMACEUTICALS INC | $4.2M | 1.53% |
| 19 | VRNA VERONA PHARMA PLC | $4.1M | 1.51% |
| 20 | KPTI KARYOPHARM THERAPEUTICS INC | $4.1M | 1.5% |
Values as reported on the Q3 2022 Form 13F. Every position is in the holdings table below.